ArticleScientific reports2025
Molecular dynamics, docking and quantum calculations reveal conformational changes influenced by CYP271A amino acid mutations related to cerebrotendinous xanthomatosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive lipid disorder caused by a deficiency in CYP27A1, the first enzyme in the bile acid biosynthesis pathway. CYP27A1 catalyzes the 7α-hydroxylation of cholesterol, playing an important role in cholesterol homeostasis. CTX leads to progressive neurological dysfunction, including cognitive impairment, epilepsy, peripheral neuropathy, and movement disorders. Missense mutations in CYP27A1 disrupt its activity, particularly at the heme binding region and the adrenodoxin-binding site. This study examined the structural effects of seven-point mutations in CYP27A1 using molecular dynamic (MD) simulations. Both mutant and wild-type (WT) proteins were modeled to observe their structural behavior. Additionally, by combining MD simulations, docking, and quantum calculations cholesterol binding was studied in WT and mutant proteins. Results indicated that mutations altered cholesterol binding mode, preventing it from adopting the correct position in the catalytic site. The substrate access channel in mutants became wider, shallower, or closed. The interaction between the isopropyl group of cholesterol and the heme was found to be crucial for the hydroxylation capacity of CYP27A1, as this interaction was only present in the cholesterol-WT complex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.